Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Island Pharmaceuticals Ltd

ILA.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.31

▲ +0.00%

Market Cap $92.14M · Vol 67.92K

Key Metrics

P/E Ratio

N/A

FWD: 3.67

Market Cap

$92.14M

Micro Cap

Div Yield

N/A

EPS Growth

-30.23%

YoY

RSI (14)

36.67

Momentum

Beta

0.67

vs Market

52W High

$0.45

23.42% below

52W Low

$0.21

61.76% above

Volume

67.92K

Avg 171.89K

P/B

8.36

Price-to-book

ROE

N/A

Return on equity

Free Float

49.24%

Public shares

Shariah Compliance8 STANDARDS

✗ Island Pharmaceuticals Ltd (ILA.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ILA.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.45%

+22.54%

-11.22%

YTD

+1.16%

+31.82%

+579.31%

+37.85%

Financials & Valuation

TTM · Annual

Total Revenue	$191.25K
Net Income	$-6,811,036.00
Revenue Growth (YoY)	+186.32%
Gross Margin	100.00%
Operating Margin	-3,741.02%
Net Profit Margin	-3,561.20%
ROE	N/A
ROA · ROIC	-91.62% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	3.67
PEG Ratio	N/A
P/S	371.60
P/B	8.36
P/FCF	N/A
EPS Growth	-30.23%
Outstanding Shares	296.10M

Technical Indicators

50-Day SMA	$0.31
200-Day SMA	$0.30
RSI (14)	36.67
Beta	0.67
52-Week High	$0.45
52-Week Low	$0.21

Volume Today	67.92K
Avg Daily Volume (30D)	171.89K
Relative Volume	0.40x
Volatility (10D)	51.95
Volatility (30D)	53.21
Free Float	49.24%

Analyst Consensus

N/A

Current Price $0.31

Mean Target N/A

52W Low$0.21 52W High$0.45

Current

Target

$0.21 $0.45

Current Analyst target

· 1 analysts

Identifiers

ExchangeASX

FIGIBBG00ZK1B0V0

ISINAU0000138869

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateFeb 25, 2027

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -1.15% ARGX.BR argenx SE -0.23% ARGX argenx SE +0.04% INSM Insmed Incorporated +1.67% 2269.HK WuXi Biologics (Cayman) Inc. -1.05%

Company Profile

Island Pharmaceuticals Limited is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.